-
Shire Receives VYVANSE Paragraph IV Notice Letter
Thursday, May 19, 2011 - 10:24am | 80Shire plc (NASDAQ: SHPGY) announces that its subsidiary Shire LLC has received a Paragraph IV Notice Letter from Sandoz Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of all strengths of lisdexamfetamine dimesylate capsules, VYVANSE. This is the first...
-
ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection
Thursday, May 19, 2011 - 9:58am | 44ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection in adults previously treated for CDI.
-
Citi Maintains High Risk on Pfizer (PFE)
Thursday, May 19, 2011 - 9:08am | 172Citi is out with its report today on Pfizer (NYSE: PFE), maintaining High Risk. In a note to clients, Citi writes, ".We rate Pfizer shares High Risk given the continued deterioration of its base business in the US, execution risk on the pipeline, and potential restructuring issues. Additional...
-
Teva and OncoGenex to Present Data on Custirsen in Prostate Cancer at the 2011 ASCO Annual Meeting
Thursday, May 19, 2011 - 8:35am | 116Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from three studies of their investigational compound custirsen in castrate resistant prostate cancer will be presented at the 47th Annual Meeting of the American Society...
-
Eli Lilly Announces Study Determined Best Dose and Showed 55% Response Rate With Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients
Thursday, May 19, 2011 - 8:12am | 82Eli Lilly and Company (NYSE: LLY) announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor, for use in combination with bortezomib in patients with previously-treated multiple myeloma. Results from the Phase I study will be presented on Sunday,...
-
ELi Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma
Thursday, May 19, 2011 - 8:11am | 94Eli Lilly and Company (NYSE: LLY) announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body. Study results demonstrated that 57 percent of patients with a soft tissue sarcoma known as adipocytic sarcoma...
-
Deutsche Bank Comments On Merck And Roche Collaboration
Thursday, May 19, 2011 - 7:55am | 93According to Deutsche Bank, Merck & Co (NYSE: MRK) announced this week that they had established a broad HCV alliance, across all major facets of the therapeutic area, including marketing, diagnostics, and R&D. Deutsche Bank said that as part of the agreement, Roche will co-promote MRK's...
-
Bank of America Maintains Buy Rating on Auxilium Pharmaceuticals
Thursday, May 19, 2011 - 7:49am | 116Bank of America is maintaining is Buy rating on shares of Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). “We lowered our sales estimates for Testim based on recent IMS trends and Xiaflex based on a more conservative ramp,” Bank of America writes. “Based on the changes, we lowered 2011E revenue to $...
-
Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
Thursday, May 19, 2011 - 7:02am | 83Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a Phase 1 clinical study for ISIS-TTRRx. ISIS-TTRRx is designed to treat transthyretin amyloidosis, a severe and rare genetic disease...
-
LifeTech Capital Downgrades Marina Biotech To Neutral, $0.30 PT
Wednesday, May 18, 2011 - 2:40pm | 108LifeTech Capital downgraded its Marina Biotech (NASDAQ: MRNA) rating from Strong Speculative Buy to Neutral and lowered its Marina Biotech price target from $2.50 to $0.30 in a research report published today. LifeTech Capital In the report, LifeTech Capital states, "Although Marina's announced...
-
Abbott Receives FDA Approval for Molecular Test for Hepatitis C
Wednesday, May 18, 2011 - 12:30pm | 50Abbott (NYSE: ABT) announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR test for measuring the viral load of hepatitis C, the leading cause of liver cancer in the United States.
-
Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal Oral Solution
Wednesday, May 18, 2011 - 8:15am | 91Perrigo Company (Nasdaq: PRGO) and its partner Synthon Pharmaceuticals, Inc. today announced that it has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Levocetirizine Solution, 2.5 mg/5ml, a generic version of UCB's Xyzal® Oral...
-
NovaBay Pharmaceuticals Reports Results from Phase 2 Clinical Trial of NVC-422 for Adenoviral Conjunctivitis
Wednesday, May 18, 2011 - 7:05am | 144NovaBay Pharmaceuticals, Inc. (NYSE: NBY) today announced the results of a Phase 2 clinical study for the treatment of adenoviral conjunctivitis. Of a total of 452 patients randomized 1:1 for treatment with NVC-422 ophthalmic solution or its vehicle as placebo, 81 patients were confirmed by...
-
GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term
Wednesday, May 18, 2011 - 6:29am | 1757Isis Pharmaceuticals Inc. (ISIS) ended the first quarter, with nearly $427 million in cash. Revenue for the three months ended March 31, 2011 was $21.1 million, compared to $29.9 million for the same period in 2010. Isis Pharmaceuticals earned a $3 million payment from GlaxoSmithKline (GSK) to...
-
Safeguard Scientifics Partner Company Advanced BioHealing to Be Acquired by Shire for $750M
Tuesday, May 17, 2011 - 5:04pm | 101Safeguard Scientifics, Inc. (NYSE: SFE) today announced that life sciences partner company Advanced BioHealing, Inc. has signed a definitive agreement to be acquired by Shire plc (NASDAQ: SHPGY). Shire has agreed to pay $750 million, in cash, for ABH in a transaction that is expected to close...